Results 291 to 300 of about 1,442,988 (353)
Some of the next articles are maybe not open access.
Hematology, 2023
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Abstract Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
de Assis, Luiz Henrique +2 more
openaire +3 more sources
Bispecific Antibodies for the Treatment of Neuroblastoma
SSRN Electronic Journal, 2022Bispecific antibodies (BsAb) are a new generation of antibody-based therapy, conveying artificial specificity to polyclonal T cells or radiohaptens. These drugs have been successfully implemented to cure hematologic malignancies and are under clinical investigation for solid tumors including HRNB.
Madelyn, Espinosa-Cotton +1 more
openaire +2 more sources
The manufacturing considerations of bispecific antibodies
Expert Opinion on Biological Therapy, 2022Introduction Antibody therapies have made huge strides in providing safe and efficacious drugs for autoimmune, cancer, and infectious diseases. These bispecific antibodies can be assembled from the basic building blocks of IgGs, resulting in dozens of ...
D. Underwood, J. Bettencourt, Z. Jawad
semanticscholar +1 more source
Bispecific Antibodies in Lymphoma
International Reviews of Immunology, 1993Journal Article ; Review ; SCOPUS: ar.j ; info:eu-repo/semantics ...
Brissinck, J +4 more
openaire +3 more sources
Engineering bispecific antibodies
Current Opinion in Biotechnology, 1993Bispecific antibodies have immense potential as reagents and in medicine. Until recently, they were made by combining monoclonal antibodies of two different specificities in vitro, or by fusion of the corresponding hybridomas. Protein engineering now offers the chance to construct a range of small 'designer' bispecific antibodies using antibody ...
Philipp Holliger, Greg Winter
openaire +3 more sources
Production of Bispecific Antibodies
Current Protocols in Immunology, 1995AbstractBispecific antibodies (bsAbs) contain two different binding specificities within a single molecule and can specifically bind two different molecules together. BsAbs can be produced by chemically cross‐linking purified antibodies or Fab fragments with reducible disulfide bonds or nonreducible thioether bonds, both of which are described in this ...
Bert J.E.G. Bast, David M. Segal
openaire +3 more sources
A revival of bispecific antibodies
Trends in Biotechnology, 2004Bispecific antibodies usually do not occur in nature but are constructed by recombinant DNA or cell-fusion technologies. Most are designed to recruit cytotoxic effector cells of the immune system effectively against pathogenic target cells. This complex task explains why, after more than 15 years of extensive research, many different formats of ...
Ralf Lutterbüse +2 more
openaire +3 more sources
Pharmacokinetics of Bispecific Antibody
Current Pharmacology Reports, 2017This article provides a brief overview of bispecific antibody (BsAb) mechanisms of action, structures, and pharmacokinetic (PK) properties, including absorption, distribution, and elimination. Recent trend in BsAb development is also introduced from a PK perspective.
Yang Chen, Yan Xu
openaire +2 more sources
Immunotherapeutic perspective for bispecific antibodies
Immunology Today, 2000Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Recent studies underline the importance of both the 'anti-trigger' and 'anti-target' modalities of BsAb for therapeutic efficacy.
Annemiek B. van Spriel +2 more
openaire +3 more sources
Catumaxomab: A bispecific trifunctional antibody
Drugs of Today, 2009The trifunctional bispecific monoclonal antibody catumaxomab has two binding specificities directed at epithelial cell adhesion molecule (EpCAM) and the T-cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells such as dendritic cells, macrophages and natural killer cells.
Marcus Schmidt +3 more
openaire +3 more sources